Fmr LLC Acquires 830,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

FMR LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 17.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,512,300 shares of the company's stock after acquiring an additional 830,000 shares during the quarter. FMR LLC owned 15.75% of Oruka Therapeutics worth $106,883,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in Oruka Therapeutics by 2,348.6% in the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock valued at $6,643,000 after acquiring an additional 328,434 shares during the period. Wellington Management Group LLP grew its position in Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock valued at $1,844,000 after purchasing an additional 12,952 shares during the period. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics during the 4th quarter valued at $54,000. Vanguard Group Inc. raised its holdings in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at $303,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Insider Activity at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par bought 88,794 shares of the company's stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the purchase, the insider now directly owns 4,148,428 shares in the company, valued at $47,458,016.32. The trade was a 2.19 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders purchased 98,339 shares of company stock worth $1,128,456. 22.67% of the stock is owned by company insiders.

Oruka Therapeutics Trading Up 7.0 %

Shares of ORKA stock traded up $0.61 during trading on Friday, hitting $9.22. The company's stock had a trading volume of 150,023 shares, compared to its average volume of 237,939. The company has a market cap of $345.02 million, a PE ratio of -1.47 and a beta of 0.47. The business has a fifty day moving average of $10.15 and a 200-day moving average of $17.37. Oruka Therapeutics, Inc. has a 52 week low of $5.49 and a 52 week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19. As a group, research analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ORKA shares. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wolfe Research assumed coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of "Buy" and an average target price of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.